MX2019014021A - Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo. - Google Patents

Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.

Info

Publication number
MX2019014021A
MX2019014021A MX2019014021A MX2019014021A MX2019014021A MX 2019014021 A MX2019014021 A MX 2019014021A MX 2019014021 A MX2019014021 A MX 2019014021A MX 2019014021 A MX2019014021 A MX 2019014021A MX 2019014021 A MX2019014021 A MX 2019014021A
Authority
MX
Mexico
Prior art keywords
cancer
diseases
preparation
metastatic
treating
Prior art date
Application number
MX2019014021A
Other languages
English (en)
Inventor
Baowei Zhao
Mingming Zhang
Hongping Yu
Shuqun Yang
Zhui Chen
Yaochang Xu
Original Assignee
Abbisko Therapeutics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbisko Therapeutics Co Ltd filed Critical Abbisko Therapeutics Co Ltd
Publication of MX2019014021A publication Critical patent/MX2019014021A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

En la presente invención se describen un derivado de N-(azaarilo)ciclo lactam-1-carboxamida, con la estructura de la fórmula (I), un método de preparación del mismo, y un uso del mismo. La serie de compuestos de la presente invención se puede aplicar ampliamente en la preparación de fármacos para tratar cánceres, tumores, enfermedades autoinmunes, enfermedades metabólicas o enfermedades metastásicas, especialmente para tratar el cáncer de ovarios, cáncer pancreático, cáncer de próstata, cáncer de mama, cáncer cervical, glioblastoma, mieloma múltiple, enfermedades metabólicas, enfermedades neurodegenerativas, metástasis de tumor primario o cáncer metastásico en huesos, y se espera su desarrollo hacia una nueva generación de fármacos inhibidores del CSF-1R. (ver Fórmula).
MX2019014021A 2017-05-24 2018-05-22 Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo. MX2019014021A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710378071 2017-05-24
PCT/CN2018/087807 WO2018214867A1 (zh) 2017-05-24 2018-05-22 N-(氮杂芳基)环内酰胺-1-甲酰胺衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
MX2019014021A true MX2019014021A (es) 2020-08-17

Family

ID=64395279

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019014021A MX2019014021A (es) 2017-05-24 2018-05-22 Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.

Country Status (13)

Country Link
US (1) US11149021B2 (es)
EP (1) EP3632907B1 (es)
JP (1) JP6934261B2 (es)
KR (1) KR102374012B1 (es)
CN (1) CN110573500B (es)
AU (1) AU2018274043C1 (es)
BR (1) BR112019024528A2 (es)
CA (1) CA3063596C (es)
MX (1) MX2019014021A (es)
PH (1) PH12019502586A1 (es)
RU (1) RU2765785C2 (es)
TW (1) TWI716686B (es)
WO (1) WO2018214867A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111548343B (zh) * 2018-06-01 2021-06-01 杭州阿诺生物医药科技有限公司 一种高活性csf1r抑制剂化合物的制备方法
BR112021003447A2 (pt) * 2018-08-24 2021-05-18 Nanjing Transthera Biosciences Co., Ltd. inibidor derivado de quinolina inovador
EP4001274A4 (en) * 2019-07-18 2023-07-26 Abbisko Therapeutics Co., Ltd. BIPHENYL DERIVATIVES FOR BLOCKING PD-1/PD-L1 INTERACTION, PROCESS FOR THEIR PREPARATION AND THEIR USE
EP4174066A4 (en) * 2020-06-17 2024-06-19 Abbisko Therapeutics Co., Ltd. IMMUNOSUPRESSANT AND MANUFACTURING PROCESS AND USE THEREOF
CN112358439A (zh) * 2020-11-26 2021-02-12 成都百泉生物医药科技有限公司 奥美拉唑工艺杂质及其制备方法
CN114907267A (zh) * 2021-02-08 2022-08-16 中国科学院上海药物研究所 用于抗肿瘤的药物组合
TW202300142A (zh) 2021-05-24 2023-01-01 大陸商上海和譽生物醫藥科技有限公司 一種結晶型csf-1r抑制劑酸式鹽及其製備方法和應用
CN115385896A (zh) * 2021-05-24 2022-11-25 上海和誉生物医药科技有限公司 一种csf-1r抑制剂中间体或其酸式盐的制备方法
CN115385897A (zh) * 2021-05-24 2022-11-25 上海和誉生物医药科技有限公司 一种csf-1r抑制剂或其酸式盐的制备方法
TW202409014A (zh) * 2022-08-30 2024-03-01 大陸商藥捷安康(南京)科技股份有限公司 喹啉衍生物抑制劑的晶型及其製備方法及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200635899A (en) * 2004-12-22 2006-10-16 Astrazeneca Ab Chemical compounds
KR20100090772A (ko) * 2007-10-12 2010-08-17 인게니움 파르마코이티칼스 게엠베하 단백질 키나제 억제제
NZ601376A (en) * 2009-12-21 2014-03-28 Array Biopharma Inc Substituted n-(1h-indazol-4-yl)imidazo[1, 2-a]pyridine-3- carboxamide compounds as cfms inhibitors
CN102408411B (zh) * 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
US9193719B2 (en) * 2013-03-15 2015-11-24 Deciphera Pharmaceuticals, Llc 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145029A2 (en) * 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
WO2014145015A2 (en) * 2013-03-15 2014-09-18 Deciphera Pharmaceuticals, Llc Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities
CN112047927A (zh) * 2013-03-15 2020-12-08 德西费拉制药有限责任公司 展现抗癌和抗增殖活性的n-酰基-n′-(吡啶-2-基)脲及类似物
EP3632906B1 (en) * 2017-05-24 2023-12-13 Abbisko Therapeutics Co., Ltd. Azaaryl derivative, preparation method therefor, and application thereof for use in pharmacy
EP3643715A4 (en) * 2017-06-19 2020-10-28 Abbisko Therapeutics Co., Ltd. HETERARYLE DERIVATIVE OF NITROGEN HAVING AN INHIBITORING ACTIVITY OF CSF1R, ITS PREPARATION PROCESS AND ITS APPLICATION
CN110461849B (zh) * 2017-06-19 2020-09-01 上海和誉生物医药科技有限公司 一种csf1r抑制剂及其制备方法和应用
CN111548343B (zh) * 2018-06-01 2021-06-01 杭州阿诺生物医药科技有限公司 一种高活性csf1r抑制剂化合物的制备方法

Also Published As

Publication number Publication date
EP3632907C0 (en) 2024-02-28
AU2018274043B2 (en) 2020-10-08
CA3063596A1 (en) 2019-12-06
JP2020520978A (ja) 2020-07-16
EP3632907B1 (en) 2024-02-28
RU2765785C2 (ru) 2022-02-02
WO2018214867A9 (zh) 2019-10-03
KR20190141215A (ko) 2019-12-23
EP3632907A4 (en) 2021-02-24
CA3063596C (en) 2022-08-30
AU2018274043C1 (en) 2021-08-19
KR102374012B1 (ko) 2022-03-14
RU2019142795A (ru) 2021-06-24
CN110573500A (zh) 2019-12-13
RU2019142795A3 (es) 2021-06-24
JP6934261B2 (ja) 2021-09-15
EP3632907A1 (en) 2020-04-08
AU2018274043A1 (en) 2019-12-12
TWI716686B (zh) 2021-01-21
PH12019502586A1 (en) 2020-09-28
BR112019024528A2 (pt) 2020-06-30
US20200071302A1 (en) 2020-03-05
TW201900632A (zh) 2019-01-01
US11149021B2 (en) 2021-10-19
CN110573500B (zh) 2020-12-08
WO2018214867A1 (zh) 2018-11-29

Similar Documents

Publication Publication Date Title
MX2019014021A (es) Derivado de n-(azaarilo)ciclo lactam-1-carboxamida, metodo de preparacion del mismo y uso del mismo.
NZ709635A (en) Bcl-2bcl-xl inhibitors and therapeutic methods using the same
MX2021002804A (es) Terapias de combinacion.
MX2020010496A (es) Inhibidores de desmetilasa-1 especifica de lisina.
EA201591145A1 (ru) Ингибиторы гистондеметилазы
EA201690531A1 (ru) ПРОИЗВОДНЫЕ 1-(5-ТРЕТ-БУТИЛ-2-АРИЛПИРАЗОЛ-3-ИЛ)-3-[2-ФТОР-4-[(3-ОКСО-4H-ПИРИДО[2,3-b]ПИРАЗИН-8-ИЛ)ОКСИ]ФЕНИЛ]МОЧЕВИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ RAF ДЛЯ ЛЕЧЕНИЯ РАКА
EA201692513A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790082A1 (ru) Ингибиторы лизин-специфической демитилазы-1
PH12015502159A1 (en) Chemical entities
MX2017000331A (es) Compuestos de aminopiridazinona como inhibidores de quinasas de proteina.
EA201790376A1 (ru) Ингибиторы лизин-специфической деметилазы-1
EA201790085A1 (ru) Ингибиторы лизин-специфической деметилазы-1
MX2015011097A (es) Inhibidores de histona desmetilasas.
PH12016502354A1 (en) Pharmaceutical composition
MX362550B (es) Inhibidores ciclicos de glutaminasa.
MX2015000129A (es) Derivados de pirimidin pirazolilo.
MX2019006299A (es) Compuestos de pirazola sustituida y metodos para usarlos para el tratamiento de enfermedades hiperproliferativas.
MX2020013320A (es) Inhibidores de ectonucleotidasa y métodos de uso de los mismos.
MX2015014591A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un compuesto de quinazolinona 5-sustituida para tratar cancer.
MX2020005659A (es) Uso de un inhibidor de parp en el tratamiento del cancer de ovario o cancer de mama resistente a la quimioterapia.
MX2016001136A (es) Derivados de oxoquinazolinil-butanamida.
PH12017500564B1 (en) Novel imidazopyridazine compounds and their use
MX2022000550A (es) Imidazopirimidinas como inhibidores de eed y uso de estas.
MX2016008042A (es) Derivados de imidazopirazinona.
MX366140B (es) Derivados de urea de piperidinas.